Revance to Participate in the Cowen 42nd Annual Health Care Conference

Rhea-AI Summary

Revance Therapeutics (Nasdaq: RVNC) will participate in the Cowen 42nd Annual Health Care Conference, a virtual event from March 7-9. CEO Mark Foley and CFO Tobin Schilke will present on March 9 at 12:50 p.m. CT / 2:50 p.m. ET. A live audio webcast of the presentation will be available on the company's Investor Relations page and will remain accessible for 30 days post-event. Revance is known for its innovative products, including the long-acting neuromodulator DaxibotulinumtoxinA, currently seeking U.S. regulatory approval.

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the Cowen 42nd Annual Health Care Conference, a fully virtual management access conference, taking place March 7-9.

Chief Executive Officer, Mark Foley, and Chief Financial Officer, Tobin Schilke, are scheduled to present on Wednesday, March 9, at 12:50 p.m. CT / 2:50 p.m. ET.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

About Revance Therapeutics, Inc.

Revance is a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation, long-acting neuromodulator product, DaxibotulinumtoxinA for Injection. Revance has successfully completed Phase 3 clinical programs for DaxibotulinumtoxinA for Injection in glabellar (frown) lines, for which the company is currently pursuing U.S. regulatory approval, and in cervical dystonia. Revance is also evaluating DaxibotulinumtoxinA for Injection in adult upper limb spasticity. Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the OPUL™ Relational Commerce Platform. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which if approved, would be the first and only generic biosimilar to Botox® and Botox® Cosmetic. For more information or to join our team visit us at www.revance.com.

“Revance Therapeutics” and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.

BOTOX® is a registered trademark of Allergan, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220302005289/en/

Investors

Revance Therapeutics, Inc.:

Jessica Serra, 626-589-1007

jessica.serra@revance.com

or

Gilmartin Group, LLC.:

Laurence Watts, 619-916-7620

laurence@gilmartinir.com

Media

Revance Therapeutics, Inc.:

Sara Fahy, 949-887-4476

sfahy@revance.com

Source: Revance Therapeutics, Inc.

Source: Revance Therapeutics, Inc.

FAQ

When will Revance Therapeutics present at the Cowen 42nd Annual Health Care Conference?

Revance Therapeutics will present on March 9, 2023, at 12:50 p.m. CT / 2:50 p.m. ET.

How can I access the Revance Therapeutics conference presentation?

The conference presentation can be accessed via a live audio webcast on Revance's Investor Relations website.

What is Revance Therapeutics known for?

Revance Therapeutics is known for its innovative aesthetic and therapeutic products, including the long-acting neuromodulator DaxibotulinumtoxinA.

What is the date of the Cowen 42nd Annual Health Care Conference?

The Cowen 42nd Annual Health Care Conference will take place from March 7-9, 2023.

What significant product is Revance Therapeutics seeking U.S. regulatory approval for?

Revance Therapeutics is seeking U.S. regulatory approval for its product DaxibotulinumtoxinA for Injection.